Strong impact of pathological node-negative on long-term overall survival of patients with triple-negative breast cancer receiving neoadjuvant chemotherapy

HIROKO NOGI1, MAKIKO KAMIO2, YASUO TORIUMI1, EIJIROU NAGASAKI3, MASAFUMI SUZUKI4 and HIROSHI TAKEYAMA1

1Department of Breast and Endocrine Surgery, Jikei University School of Medicine, Tokyo 105-8461; 2Department of Surgery, The Jikei University Kashiwa Hospital, Chiba 277-8567; Departments of 3Medical Oncology and Hematology, and 4Pathology, Jikei University School of Medicine, Tokyo 105-8461, Japan

Received July 5, 2020; Accepted February 5, 2021

DOI: 10.3892/mco.2021.2261

Abstract. Triple-negative breast cancer (TNBC) has a high pathological complete response (pCR) rate; however patients without a high pCR are reported to have a poor prognosis. The current study investigated the long-term overall survival of patients with TNBC who received neoadjuvant chemotherapy (NAC) and analyzed various prognostic factors including basal marker and claudin expressions. Between November 2005 and March 2012, the current study retrospectively reviewed the records of 323 patients with breast cancer who received anthracycline followed by taxane as NAC at the Jikei University Hospital. Basal marker and claudin expression was determined via immunohistochemistry. The median age of the patients was 53.0 years. Of the 323 patients, 26 (8%) achieved a pCR, including 13 patients (19.7%) with TNBC and 13 (5.1%) with non-TNBC (P<0.001). Of the 66 patients with TNBC, 13 (19.7%) demonstrated recurrence and 8 (12.1%) died after a median follow-up time of 111.5 months [10-year disease-free survival (DFS), 80.3%; 95% confidence interval (CI), 0.68-0.88; 10-year overall survival (OS), 84.8%; 95% CI, 0.72-0.92]. Of the 257 patients with non-TNBC, 45 (17.5%) patients demonstrated recurrence and 26 (10.1%) died (10-year DFS, 82.1%; 95% CI, 0.76-0.87; 10-year OS, 88.6%; 95% CI, 0.83-0.92). There was no statistical difference between the patients with and without TNBC. In the TNBC group, patients with pathological node-negative status survived without distant recurrence. Additionally, negative lymphovascular infiltration was another favorable prognostic factor. Patients with TNBC who received NAC demonstrated comparably high prognoses to non-TNBC patients. Overall, pathological node status after NAC had a strong impact on the prognosis of patients with TNBC.

Introduction

Breast cancer is one of the most common cancers in women worldwide (1,2). Triple-negative breast cancer (TNBC) is characterized by the lack of estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor-2 (HER2) expression. TNBC is reported to account for 10-15% of all sporadic breast cancers. Compared to non-TNBCs, they are generally larger, show higher grade, have lymph node involvement at the time of diagnosis, and are biologically more aggressive (3-5). In previous studies, 20-56% of patients with TNBC were reported to achieve a pathological complete response (pCR) after neoadjuvant chemotherapy (NAC). Despite higher response rates to NAC, the patients with TNBC who did not achieve pCR had a higher rate of distant recurrence and poorer prognosis compared to the non-TNBC group. Disease-free survival (DFS) of patients with TNBC was reported to be 50-60% (6-13). However, the median follow-up periods in those reports were relatively short (3-6 years), and the long-term overall survival of patients with TNBC who did not achieve pCR have not been reported. Furthermore, reports of a pooled analysis included various regimens for NAC.

Gene expression profiling has established several distinct breast cancer molecular subtypes, including luminal A and B, HER2-positive, basal-like, and claudin-low (14-16). TNBCs account for 39-54% of basal-like and 25-39% of claudin-low cases. Each breast cancer is associated with different clinical outcomes, biological features, and treatment responses (17).
Epithelial-derived cancers often show high or low expression of claudins. These proteins are the most important structural and functional components of tight junction integral membrane proteins. However, the association between claudin expression and prognosis is unknown (18).

In this study, we retrospectively investigated the long-term overall survival of patients with TNBC who received NAC and their prognostic factors including basal marker and claudin expression.

Patients and Methods

Patients and treatment. We retrospectively reviewed the records of 323 consecutive breast cancer patients who received NAC at the Jikei University Hospital between November 2005 and March 2012. This study was conducted in accordance with the Helsinki Declaration of 1975, as revised in 1983, and was approved by the Ethics Committee of the Jikei University School of Medicine; patient consent was also obtained. We evaluated the age of patients, clinicopathological characteristics such as clinical tumor size and clinical lymph node status before NAC, ER, PgR, and HER2 expression, pathological tumor size, pathological lymph node status, lymphovascular infiltration, epidermal growth factor receptor (EGFR), cytokeratin (CK) 5/6 as the basal marker, claudin-3 expression, and survival data for the patients. Lymphovascular infiltration was evaluated with the operative sample after NAC. A clinically node-positive axilla was defined as the presence of palpable mass in the nodal basin and, when assessed using ultrasound, magnetic resonance imaging, or computed tomography images, the presence of abnormal lymph nodes. When these had a suspected cancerous appearance on images, positivity was confirmed via fine needle aspiration.

All patients received NAC with four cycles of epirubicin (100 mg/m²), 5-fluorouracil (500 mg/m²), and cyclophosphamide (500 mg/m²), followed by four cycles of docetaxel (100 or 75 mg/m²). If patients were HER2-positive, trastuzumab was administered concurrently with docetaxel and adjuvant trastuzumab for one-year duration. A five-year adjuvant hormonal therapy was followed if the patients were hormone receptor positive. Patients who underwent breast conserving surgery received whole breast radiotherapy, and regional lymph node radiotherapy was used for patients with ≥4 -positive nodes. Post-mastectomy radiation therapy was administered to patients with initial tumors ≥5 cm or those with ≥4 positive nodes.

Systemic and breast examinations were performed before neoadjuvant chemotherapy, before surgery, and every 12 months postoperatively using chest and abdominal computed tomography, mammograms, breast ultrasonography, brain magnetic resonance imaging, and bone scans.

Pathology assessment. Immunohistochemistry (IHC) was evaluated using core needle samples before NAC and to ensure accuracy we used positive staining tissue as a control. IHC was performed according to the standard protocol on 3 μm sections of formalin-fixed paraffin-embedded tissue. A staining score of 3+ according to the HercepTest criteria was considered positive; a result of 2+ was considered positive only if confirmed by fluorescence in situ hybridization with an amplification ratio of ≥2.0. Furthermore, on 3 μm FFPE tissue sections, the EGFR and CK5/6 expression were determined using IHC with mouse monoclonal antibodies (EGFR; dilution, 1:10; Leica Biosystems, cat. no. EGFR-L-CE, Wetzlar, CK5/6; dilution, 1:50; Agilent Technologies, cat. no. M7273). The expression of claudin-3 was determined using IHC with a rabbit polyclonal antibody (dilution, 1:100; Invitrogen; Thermo Fisher Scientific, Inc. cat. no. 18-7340) on 5 μm FFPE tissue sections. EGFR, CK5/6 and claudin-3 staining results were considered positive if any cytoplasmic and/or membranous invasive carcinoma cell staining was observed. If EGFR and/or CK5/6 were positive, the sample was considered basal marker positive.

pCR was defined as no evidence of residual tumor cells in the breast and in the lymph nodes.

Statistical analysis. We conducted Fisher's exact test to assess the association of clinicopathological characteristics and pCR between the patients with and without TNBC and that between basal marker and claudin expressions and pCR in the TNBC group. DFS was measured from the date of surgery to the date of any recurrence or the last follow-up. Overall survival (OS) was measured from the date of diagnosis to the date of death or the last follow-up. The Kaplan-Meier method was used to generate survival curves and the cumulative incidence of events. Cramér-von Mises test was used to assess the differences in Kaplan-Meier curves. The Cox regression model was used to identify the potential prognostic and predictive indicators. All significant tests were two-sided, a P-value ≤0.05 was considered statistically significant. All analyses were performed using Stata statistical software (Stata SE 10; StataCorp LP).

Results

Patients and tumor characteristics. The median patients age was 53 years (range; 24-75 years). Table I shows the patient details and tumor characteristics. TNBC accounted for 20.4% of the total breast cancer. Age, clinical tumor size and node status before NAC, pathological tumor size and node status, and lymphovascular infiltration were not significantly different between TNBC and non-TNBC patients. Among the 323 patients, 26 patients (8%) achieved a pCR including 13 patients (19.7%) with TNBC and 13 (5.1%) without TNBC. The pCR rate of TNBC was significantly higher than that of the non-TNBC group (P<0.001). The reduction in tumor status was significant in patients with TNBC (P=0.001).

Correlation between pCR and expression of basal marker and claudin in TNBC. Core needle samples before NAC were available for basal marker and claudin staining for 43 patients with TNBC. We observed basal marker positivity in 25 (58.1%) cases of TNBCs and claudin-3 positivity in 21 (48%) cases with TNBC. Table II shows the associations between basal marker and claudin expressions and pCR. The
pCR rate of basal marker-positive tumors was 24% and that of claudin-positive tumors was 25%. Basal marker-negative and claudin-negative tumors had the lowest pCR rate (0%) whereas basal marker-negative and claudin-positive tumors had the highest pCR rate (33.3%). The association between the basal marker and/or claudin expression and pCR rate were not statistically significant (P=0.134).

Survival. After a median follow-up time of 111.5 (range: 6.8-170.2) months, 23 patients showed local recurrence

Table I. Patient and tumor characteristics by subtype.

| Characteristics                              | Triple-negative (n=66) | Non Triple-negative (n=257) | P-value |
|---------------------------------------------|-----------------------|----------------------------|---------|
| Age (years)                                 | 0.395                 |                            |         |
| <50                                         | 22                    | 103                        |         |
| ≥50                                         | 44                    | 154                        |         |
| Clinical tumor size before NAC (cm)         | 0.625                 |                            |         |
| ≤5                                          | 49                    | 199                        |         |
| >5                                          | 17                    | 58                         |         |
| Clinical node status before NAC             | >0.999                |                            |         |
| Negative                                    | 38                    | 147                        |         |
| Positive                                    | 28                    | 110                        |         |
| Clinical stage before NAC                   | 0.285                 |                            |         |
| I                                           | 8                     | 18                         |         |
| II                                          | 41                    | 181                        |         |
| III                                         | 17                    | 58                         |         |
| Estrogen receptor                           | <0.001                |                            |         |
| Negative                                    | 66                    | 38                         |         |
| Positive                                    | 0                     | 219                        |         |
| Progesterone receptor                       | <0.001                |                            |         |
| Negative                                    | 66                    | 95                         |         |
| Positive                                    | 0                     | 162                        |         |
| HER2                                        | <0.001                |                            |         |
| Negative                                    | 66                    | 178                        |         |
| Positive                                    | 0                     | 79                         |         |
| Pathological tumor size after NAC (cm)      | 0.311                 |                            |         |
| ≤5                                          | 55                    | 226                        |         |
| >5                                          | 11                    | 31                         |         |
| Pathological node status after NAC          | 0.249                 |                            |         |
| Negative                                    | 47                    | 161                        |         |
| Positive                                    | 19                    | 96                         |         |
| Lymphovascular infiltration after NAC       | >0.999                |                            |         |
| Negative                                    | 58                    | 226                        |         |
| Positive                                    | 8                     | 31                         |         |
| pCR                                         | <0.001                |                            |         |
| Yes                                         | 13                    | 13                         |         |
| No                                          | 53                    | 244                        |         |
| Tumor status                                | 0.001                 |                            |         |
| Downstaging                                 | 50                    | 138                        |         |
| Stable                                      | 16                    | 119                        |         |
| Nodal status                                | 0.297                 |                            |         |
| Downstaging                                 | 16                    | 47                         |         |
| Stable                                      | 50                    | 210                        |         |

HER2, human epidermal growth factor receptor 2; pCR, pathological complete response; NAC, neoadjuvant chemotherapy. Clinical stage was determined using the 8th edition of the Union Internationale Contra Cancrum.
and 47 patients showed distant recurrence. Breast cancer related-disease occurred in 13 (19.7%) patients with TNBC (5-year DFS: 80.3%, 95% CI: 0.68-0.88; 10-year DFS: 80.3%, 95% CI: 0.68-0.88) and in 45 (17.5%) patients with non-TNBC (5-year DFS: 87.5%, 95% CI: 0.83-0.91; 10-year DFS 82.1%, 95% CI: 0.76-0.87). Fig. 1A shows the cumulative DFS by TNBC versus non-TNBC (Cramér-von Mises P<0.001). Overall, 8 (12.1%) patients with TNBC (5-year OS: 86.8%, 95% CI: 0.74-0.93; 10-year OS: 84.8%, 95% CI: 0.72-0.92) and 26 (10.1%) patients with non-TNBC died (5-year OS: 96.2%, 95% CI: 0.93-0.98; 10-year OS: 88.6%, 95% CI: 0.83-0.92). Fig. 1B shows the cumulative OS by TNBC versus non-TNBC (Cramér-von Mises P<0.001). Table III summarizes the results of univariate and multivariate analyses for survival. In the univariate analysis for DFS and OS, clinical tumor size, node status before NAC, pathological tumor size, pathological node status, and lymphovascular infiltration were statistically significant prognostic factors. In the multivariate analysis for DFS and OS, clinical tumor size, node status, and lymphovascular infiltration were statistically significant prognostic factors. In the multivariate analysis for OS, pathological node-positive and lymphovascular infiltration were independent worse prognostic factors. Fig. 2 shows the cumulative survival of patients with TNBC. The patients with pathological node-negative status showed significantly good prognosis. (log rank P<0.001). Among TNBC patients with pathological node-positive status, negative lymphovascular infiltration was a significant favorable prognostic factor (Table IV).

Discussion
Our study showed that the long-term overall survival of patients with TNBC who received NAC containing anthracycline and taxane was favorable compared to that in non-TNBC patients. Especially, patients with TNBC who achieved pathological

Table II. Expression of basal marker and claudin, and the association between pathological complete response rate and their expression.

| Marker expression | N   | pCR, n (%) | P-value |
|-------------------|-----|------------|---------|
| Basal marker      |     |            | 0.712   |
| Positive          | 25  | 6 (24.0)   |         |
| Negative          | 18  | 3 (16.7)   |         |
| Claudin           |     |            | 0.708   |
| Positive          | 21  | 6 (25.0)   |         |
| Negative          | 22  | 3 (15.8)   |         |
| Basal marker and Claudin | | | 0.134   |
| Basal marker positive, claudin positive | 15 | 3 (20.0) |         |
| Basal marker positive, claudin negative | 10 | 3 (30.0) |         |
| Basal marker negative, claudin positive | 9  | 3 (33.3) |         |
| Basal marker negative, claudin negative | 9  | 0 (0.0)  |         |

pCR, pathological complete response.
node-negative status after NAC survived during the median follow-up of 111.5 months.

A previous study using PAM 50 showed that the new subtype ‘claudin-low’ had a preponderance for low to absent expressions of E-cadherin and claudin-3, and almost all TNBC cases were either basal-like or claudin-low (16). They showed different prognosis among subtypes. In this study, we evaluated the efficiency of IHC for claudin-3 and basal markers such as EGFR and CK5/6 to predict pCR and prognosis instead of gene profiling. The expression of claudin-3 and basal markers was not associated with prognosis and the response to neoadjuvant chemotherapy. IHC is an inexpensive technique; however, it failed to substitute for the gene profiles.

On the contrary, Lehman and colleagues reported that TNBC could be classified into seven subtypes. These seven TNBC subtypes were characterized based on gene ontologies and differential gene expressions and were labeled as basal-like 1, basal-like 2, immunomodulatory, mesenchymal, mesenchymal stem-like, luminal androgen receptor, and unstable (19). They also reported the survival analysis and chemotherapy response (20), and advocated the implications for NAC according to the seven subtypes (21). In their study, basal-like 1 and basal-like 2 showed different prognosis and response to standard chemotherapy. The basal-like 2 subtype had unique ontologies involving growth factor signaling and new therapeutic applications were required.

In our study, the multivariate analyses showed that pathological node status was an independent prognostic factor.
for overall survival but not for disease-free survival. On the other hand, clinical and pathological tumor statuses were independent prognostic factors for disease-free survival but not for overall survival. These contradictory results might stem from the fact that patients who had only locoregional lymph node metastasis or breast recurrence without distant metastasis were alive for long periods, and that such patients had large tumors and negative lymph nodes.

Our study showed that patients with TNBC without any recurrence within 4 years had an excellent prognosis. For patients with TNBC, achievement of a pathological node-negative status was the most desirable result for improving prognosis. Pathological node-positive status or positive lymphovascular infiltration after NAC might be observed because of resistance to chemotherapy and may lead to worse prognosis. Hence, we need to predict chemosensitivity and develop specific treatments. A recent study has shown that adjuvant capecitabine therapy improved the outcomes for patients with TNBC without a pCR after standard NAC with anthracycline and taxane (22). Furthermore, various studies and clinical trials including targeted therapies, such as tyrosine kinase inhibitors, poly ADP-ribose polymerase-1 inhibitors, immune checkpoints, anti-androgens, and histone deacetylase inhibitors, have been conducted to improve the prognosis of patients with TNBC (23-26).

The limitations of this study need to be considered carefully. This is a retrospective study conducted at a single institute and the number of patients was limited, especially in the TNBC group. The strength of this study lies in the use of a single regimen as the NAC and the long follow-up periods for evaluating the survival of patients who received NAC.

In conclusion, patients with TNBC who showed no distant recurrence within 4 years after surgery had a good prognosis and their survival curve crossed with that of the non-TNBC group. For the patients with TNBC, pathological node-negative status and negative lymphovascular infiltration were favorable prognostic factors.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

HN contributed to the conception, design, analysis and integrity of the current study. MK, YT, EN and HT performed the experiments. MS performed the pathological evaluation. NH and MK confirmed the authenticity of all the raw data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by the Ethics Committee of Jikei University School of Medicine, and patient consent was obtained.

Patient consent for publication

Not applicable.

Competing interest

The authors declare that they have no competing interests.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018; GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394-424, 2018.
2. Hu K, Ding P, Wu Y, Tian W, Pan T and Zhang S: Global patterns and trends in the breast cancer incidence and mortality according to sociodemographic indices: An observational study based on the global burden of disease 2017 study. Breast Cancer Res Treat 199: 233-245, 2019.
3. Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med 363: 1938-1948, 2010.
4. Malorni L, Shetty PB, De Angelis C, Hilsenbeck S, Rimawi MF, Elledge R, Osborne CK, De Placido S and Arpino G: Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat 136: 795-804, 2012.
5. Bianchini G, Balko JM, Mayer IA, Sanders ME and Gianni L: Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 13: 654-690, 2016.
6. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou CM: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13: 2329-2334, 2007.
7. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia IA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26: 1275-1281, 2008.
8. Noghi K, Kobayashi T, Suzuki M, Tabei I, Kawase K, Toriumi Y, Fujishima H and Uchida K: EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer. Oncol Rep 21: 413-417, 2009.
9. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hufrich J, Huober J, et al: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30: 1796-1804, 2012.
10. Hahnen E, Léderer B, Hauke J, Lobli S, Kröber S, Schneeweiss A, Denkert C, Fasching PA, Blohmer JU, Jackisch C, et al: Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: Secondary analysis of the GeparSixto randomized clinical trial affiliations expanded. JAMA Oncol 3: 1378-1385, 2017.
11. Bonnefoi H, Litière S, Piccart M, Macgrogan G, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Moldovan C, et al: Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: A landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. Ann Oncol 25: 1128-1136, 2014.
12. Cortazar F, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, et al: Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet 384: 164-172, 2014.
13. Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M and Akiyama F: Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG. Breast Cancer 22: 486-495, 2015.
14. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT,Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature 406: 747-52, 2000.

15. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001.

16. Herschkowitz JI, Simin K, Weigman VI, Mikaelian I, Usary J, HuZ, Rasmussen KE, Jones LP, Assenfia S, Chandrasekharan S, et al: Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8: R76, 2007.

17. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X and Perou CM: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12: R68, 2010.

18. Ding L, Lu Z, Lu Q and Chen YH: The claudin family of proteins in human malignancy: A clinical perspective. Cancer Manag Res 5: 367-375, 2013.

19. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750-2767, 2011.

20. Masuda H, Baggerty KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, et al: Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 19: 5533-5540, 2013.

21. Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME and Pietenpol JA: Refinement of triple-negative breast cancer molecular subtypes: Implications for neoadjuvant chemotherapy selection. PLoS One 11: e0157368, 2016.

22. Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, et al: Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376: 2147-2159, 2017.

23. Denkert C, Lieglik C, Tutt A and von Minckwitz G: Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet 389: 2430-2442, 2017.

24. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, et al: Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379: 2108-2121, 2018.

25. Damaskos C, Garmpi A, Nikolettos K, Vavourakis M, Diamantis E, Patsouras A, Farmaki P, Nonni A, Dimitroulis D, Mantas D, et al: Triple-negative breast cancer: The progress of targeted therapies and future tendencies. Anticancer Res 39: 5285-5296, 2019.

26. Nedeljković M and Damjanović A: Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge. Cells 8: 957, 2019.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.